SCHEDULE 13G 0001453072 XXXXXXXX LIVE Common Stock, par value $0.001 per share 06/30/2025 0000949858 Achieve Life Sciences, Inc. 004468500 22722 29th Drive SE Suite 100 Bothell WA 98021 Rule 13d-1(b) Alyeska Investment Group, L.P. DE 0.00 4918822.00 0.00 4918822.00 4918822.00 N 9.9 IA Alyeska Fund GP, LLC DE 0.00 4918822.00 0.00 4918822.00 4918822.00 N 9.9 OO Anand Parekh X1 0.00 4918822.00 0.00 4918822.00 4918822.00 N 9.9 IN Achieve Life Sciences, Inc. 22722 29th Drive SE, Suite 100, Bothell, WA 98021 (i) Alyeska Investment Group, L.P. (ii) Alyeska Fund GP, LLC (iii) Anand Parekh (i) 77 West Wacker Drive, 7th Floor, Chicago, IL 60601 (ii) 77 West Wacker Drive, 7th Floor, Chicago, IL 60601 (iii) 77 West Wacker Drive, 7th Floor, Chicago, IL 60601 (i) Alyeska Investment Group, L.P. - Delaware (ii) Alyeska Fund GP, LLC - Delaware (iii) Anand Parekh - United States of America N IA HC 4,918,822 9.9% 0 4,918,822 0 4,918,822 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Item 4. Ownership: The reporting persons are the beneficial owners of 3,504,333 shares of Common Stock of the Issuer and hold warrants to purchase 2,804,333 shares of the Issuer's Common Stock (the "Warrants"). However, per their terms, the Warrants can only be exercised into such number of shares that would constitute 9.9% of the total number of Common Stock of the Issuer outstanding immediately after giving effect to the issuance of Common Stock upon exercise of this Warrant by the Holder. Accordingly, as of June 30, 2025 the reporting persons may only exercise up to 1,414,489 Ordinary Shares under the Warrant Agreement, and as such, is reporting beneficial ownership of only such number of shares. The percentage calculation assumes that there are currently 49,685,072 outstanding Common Stock of the Issuer, based on the Issuer's Prospectus filed with the Securities and Exchange Commission on June 27, 2025. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Alyeska Investment Group, L.P. Jason Bragg 08/14/2025 Alyeska Fund GP, LLC Jason Bragg 08/14/2025 Anand Parekh Anand Parekh 08/14/2025